Acute decompensated heart failure update

John R. Teerlink, Khalid Alburikan, Marco Metra, Jo E. Rodgers

Research output: Contribution to journalArticle

  • 5 Citations

Abstract

Acute decompensated heart failure (ADHF) continues to increase in prevalence and is associated with substantial mortality and morbidity including frequent hospitalizations. The American Heart Association is predicting that more than eight million Americans will have heart failure by 2030 and that the total direct costs associated with the disease will rise from $21 billion in 2012 to $70 billion in 2030. The increase in the prevalence and cost of HF is primarily the result of shifting demographics and a growing population. Although many large, randomized, controlled clinical trials have been conducted in patients with chronic heart failure, it was not until recently that a growing number of studies began to address the management of ADHF. It is the intent of this review to update the clinician regarding the evaluation and optimal management of ADHF.

LanguageEnglish (US)
Pages53-62
Number of pages10
JournalCurrent Cardiology Reviews
Volume11
Issue number1
StatePublished - Jan 1 2015

Fingerprint

Heart Failure
Costs and Cost Analysis
Hospitalization
Randomized Controlled Trials
Demography
Morbidity
Mortality
Population

Keywords

  • Acute decompensated heart failure
  • Diuretics
  • Inotropes
  • Vasodilators

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Teerlink, J. R., Alburikan, K., Metra, M., & Rodgers, J. E. (2015). Acute decompensated heart failure update. Current Cardiology Reviews, 11(1), 53-62.

Acute decompensated heart failure update. / Teerlink, John R.; Alburikan, Khalid; Metra, Marco; Rodgers, Jo E.

In: Current Cardiology Reviews, Vol. 11, No. 1, 01.01.2015, p. 53-62.

Research output: Contribution to journalArticle

Teerlink, JR, Alburikan, K, Metra, M & Rodgers, JE 2015, 'Acute decompensated heart failure update' Current Cardiology Reviews, vol. 11, no. 1, pp. 53-62.
Teerlink JR, Alburikan K, Metra M, Rodgers JE. Acute decompensated heart failure update. Current Cardiology Reviews. 2015 Jan 1;11(1):53-62.
Teerlink, John R. ; Alburikan, Khalid ; Metra, Marco ; Rodgers, Jo E./ Acute decompensated heart failure update. In: Current Cardiology Reviews. 2015 ; Vol. 11, No. 1. pp. 53-62
@article{b13c2b3891d0451f93f781e632a104cc,
title = "Acute decompensated heart failure update",
abstract = "Acute decompensated heart failure (ADHF) continues to increase in prevalence and is associated with substantial mortality and morbidity including frequent hospitalizations. The American Heart Association is predicting that more than eight million Americans will have heart failure by 2030 and that the total direct costs associated with the disease will rise from $21 billion in 2012 to $70 billion in 2030. The increase in the prevalence and cost of HF is primarily the result of shifting demographics and a growing population. Although many large, randomized, controlled clinical trials have been conducted in patients with chronic heart failure, it was not until recently that a growing number of studies began to address the management of ADHF. It is the intent of this review to update the clinician regarding the evaluation and optimal management of ADHF.",
keywords = "Acute decompensated heart failure, Diuretics, Inotropes, Vasodilators",
author = "Teerlink, {John R.} and Khalid Alburikan and Marco Metra and Rodgers, {Jo E.}",
year = "2015",
month = "1",
day = "1",
language = "English (US)",
volume = "11",
pages = "53--62",
journal = "Current Cardiology Reviews",
issn = "1573-403X",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Acute decompensated heart failure update

AU - Teerlink,John R.

AU - Alburikan,Khalid

AU - Metra,Marco

AU - Rodgers,Jo E.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Acute decompensated heart failure (ADHF) continues to increase in prevalence and is associated with substantial mortality and morbidity including frequent hospitalizations. The American Heart Association is predicting that more than eight million Americans will have heart failure by 2030 and that the total direct costs associated with the disease will rise from $21 billion in 2012 to $70 billion in 2030. The increase in the prevalence and cost of HF is primarily the result of shifting demographics and a growing population. Although many large, randomized, controlled clinical trials have been conducted in patients with chronic heart failure, it was not until recently that a growing number of studies began to address the management of ADHF. It is the intent of this review to update the clinician regarding the evaluation and optimal management of ADHF.

AB - Acute decompensated heart failure (ADHF) continues to increase in prevalence and is associated with substantial mortality and morbidity including frequent hospitalizations. The American Heart Association is predicting that more than eight million Americans will have heart failure by 2030 and that the total direct costs associated with the disease will rise from $21 billion in 2012 to $70 billion in 2030. The increase in the prevalence and cost of HF is primarily the result of shifting demographics and a growing population. Although many large, randomized, controlled clinical trials have been conducted in patients with chronic heart failure, it was not until recently that a growing number of studies began to address the management of ADHF. It is the intent of this review to update the clinician regarding the evaluation and optimal management of ADHF.

KW - Acute decompensated heart failure

KW - Diuretics

KW - Inotropes

KW - Vasodilators

UR - http://www.scopus.com/inward/record.url?scp=84919608010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919608010&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 53

EP - 62

JO - Current Cardiology Reviews

T2 - Current Cardiology Reviews

JF - Current Cardiology Reviews

SN - 1573-403X

IS - 1

ER -